Objective
"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreatable residual cardiovascularrisk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process."
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- social sciences sociology demography mortality
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine cardiology cardiovascular diseases arteriosclerosis
- social sciences economics and business business and management business models
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-HEALTH-2013-INNOVATION-1
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
2595 DA Den Haag
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.